AKBMo — Aker Biomarine ASA Balance Sheet
0.000.00%
- NOK7.78bn
- NOK9.54bn
- $199.00m
- 28
- 11
- 100
- 40
Annual balance sheet for Aker Biomarine ASA, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | R2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | Interim Report | ARS | Interim Report |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 9.09 | 9.15 | 22.3 | 25.3 | 15 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 64.1 | 60.4 | 82.7 | 66.2 | 55.1 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 223 | 240 | 299 | 283 | 195 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 280 | 339 | 343 | 351 | 51.6 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 700 | 757 | 825 | 827 | 380 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 70.9 | 77.3 | 105 | 113 | 53.2 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 327 | 387 | 446 | 461 | 214 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 373 | 370 | 379 | 367 | 167 |
| Total Liabilities & Shareholders' Equity | 700 | 757 | 825 | 827 | 380 |
| Total Common Shares Outstanding |